A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2022-08-10
Target enrollment:
Participant gender:
Summary
The yearly incidence of soft-tissue sarcomas (STS) in the USA is roughly 11,280 cases, and
metastatic STS have a median overall survival of about 12 months. Sarcomas of the soft tissue
are a heterogeneous group of malignant tumors of mesenchymal origin that originate in
connective tissue. Local control with wide surgical resection with or without adjuvant
radiation has a success rate of close to 90%. However, approximately 40% to 50% of patients
with a large (>5 cm), deep, high-grade soft-tissue sarcoma eventually develop distant
metastases, primarily in the lung. Therefore, overall survival of metastatic STS remained
still poor, less than 1 year. Therefore, current clinical trials with various targeted agents
are ongoing add on the doxorubicin monotherapy.
Investigator planned to conduct the phase I/II trial of durvalumab in combination with
standard chemotherapy, doxorubicin for metastatic/recurred sofe tissue sarcoma.